Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH
The Policy: Medicare's BALANCE Model In July 2026, Medicare launches the GLP-1 Bridge, an interim six-month pilot covering semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) for beneficiaries with a BMI of 30 or higher, or BMI of 27 or higher with an obesity-related comorbidity (diabetes, cardiovascular disease, hypertension)
Use of sodium-glucose co-transporter 2 (SGLT-2) inhibitors is currently classified as off-label in individuals less than 18 years of age in Canada
Combined mechanosensing studies can use functional overload (synergist ablation) as the mechanical stimulus and MGF neutralising antibody versus exogenous MGF-Ct24E infusion to dissect endogenous vs exogenous MGF contribution to satellite cell response